Home › Research › Biomarkers
Development of a novel in‐house blood biomarker panel for early diagnosis of Alzheimer’s disease
Prita Riana Asih, Juan Lantero Rodriguez, Steve Pedrini, EMS Bandara, Kristie Stefanoska, Henrik Zetterberg, Arne Ittner, Kaj Blennow et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
We have successfully generated specific high affinity monoclonal antibodies against p -Tau217, p -Tau205, and N-terminus GFAP and have confirmed that these antibodies have the necessary specificity and sensitivity for the Simoa platform. The development of Simoa assays will be validated in a highly characterised control and Alzheimer cohort The Australian Imaging, Biomarker, and Lifestyle (AIBL) and a novel panel of the best 3 biomarkers established.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Asih, P. R., Rodriguez, J. L., Pedrini, S., Bandara, E. M. S., Stefanoska, K., Zetterberg, H., et al. (2025). Development of a novel in‐house blood biomarker panel for early diagnosis of Alzheimer’s disease. Alzheimer s & Dementia. https://doi.org/10.1002/alz70861_108325
Vancouver
Asih PR, Rodriguez JL, Pedrini S, Bandara EMS, Stefanoska K, Zetterberg H, et al. Development of a novel in‐house blood biomarker panel for early diagnosis of Alzheimer’s disease. Alzheimer s & Dementia. 2025. doi:10.1002/alz70861_108325. PMID: 41433570.
BibTeX
@article{asih2025-41433570,
author = {Asih, Prita Riana and Rodriguez, Juan Lantero and Pedrini, Steve and Bandara, EMS and Stefanoska, Kristie and Zetterberg, Henrik and Ittner, Arne and Blennow, Kaj and others},
title = {{Development of a novel in‐house blood biomarker panel for early diagnosis of Alzheimer’s disease}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70861_108325},
pmid = {41433570},
url = {https://doi.org/10.1002/alz70861_108325}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We have successfully generated specific high affinity monoclonal antibodies against p -Tau217, p -Tau205, and N-terminus GFAP and have confirmed that these antibodies have the necessary specificity and sensitivity for the Simoa platform.
- The development of Simoa assays will be validated in a highly characterised control and Alzheimer cohort The Australian Imaging, Biomarker, and Lifestyle (AIBL) and a novel panel of the best 3 biomarkers established.
Why it matters
Researchers generated monoclonal antibodies against p-Tau217, p-Tau205, and N-terminus GFAP and confirmed they work on the Simoa platform. This is early laboratory work; the assays still need to be validated in a control and Alzheimer cohort before any clinical use.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthModerate
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Ralph Nigel Martins: h-index 117 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 16 institution(s) in 6 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41433570) |
| Free to read | 2 / 2 | Free to read |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70861_108325
- PubMed: 41433570
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.